Some movement in the U.S. toward consideration of better trial design and analysis is has been afoot, but not a mechanism for offering independent analysis for inclusion in published reports.

FORBES: How Can Big Pharma Restore A Reputation?

Data and rational analysis offer the hope that we can be less subjective in our consideration of alternatives and potential courses of action, thereby freeing us from the many biases we bring to the table.

FORBES: Meeting the Big Data challenge: DON'T be objective

They grasp that conflicts of interest are ubiquitous in life and that intelligent people take them into consideration when appraising a particular report, tip, argument or analysis.

FORBES: Magazine Article